Advanced Accelerator Applications

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Approved for marketing

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Jul 14, 2026

No longer available

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Earlier

Aug 31, 2022TrialStudy to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Jan 25, 2021TrialPost-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Jan 8, 2020TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

May 24, 2019Trial[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

Nov 28, 2018TrialPost-Authorization Long-Term Safety Study of LUTATHERA

Jul 3, 2018Trial[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

4 more events

May 24, 2018Trial177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

May 23, 2018Trial68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Jan 26, 2018FDALutathera — LUTATHERA

Sep 18, 2017Trial99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Lutathera9 patentsJul 25, 2038 Lutathera9 patentsJan 25, 2039

Regulatory

Regulatory Timeline

20181 event

FDAJan 26

Lutathera — LUTATHERA

Application NDA208700 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)